Study suggests lean muscle mass loss can be minimized during weight loss therapy using newer incretin obesity drugs
New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across 6 months of treatment. The study is by Dr Dinabel Peralta-Reich, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell; Lenox Hill Hospital, Northwell Health, New York City, NY, USA, and Dr Alexandra Filingeri, New York Weight Wellness Medicine, New York City, NY, USA, and colleagues.
GLP-1 (glucagon-like peptide-1) receptor agonists, ...










